Home/ Stocks/ LCTX

Lineage Cell Therapeutics, Inc.

LCTX XASE

$1.10 -0.03 (-2.65%) ▼ 15-min delayed

Open

$1.10

High

$1.14

Low

$1.08

Volume

833.6K

Market Cap

$281.71M

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 77 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$1.73M	$-4,789,000	$-0.02
FY 2025	$14.56M	$-63,367,000	$-0.28
Q3 2025	$3.68M	$-29,752,000	$-0.13
Q2 2025	$2.77M	$-30,364,000	$-0.13

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for LCTX yet. Check out our latest market news or earnings calendar.

Get LCTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Lineage Cell Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.